Parkinson’s/Alzheimer’s/Dementia Genetic Test (PAD)
Parkinson’s/Alzheimer’s/Dementia Genetic Test (PAD)
Regular price
Sale price
Regular price
Sold out
Unit price
- +

Important Note: After purchasing, you will receive two separate emails:

  1. Doc-U-Sign which needs to be filled out and submitted
  2. Instructions on next steps  

Targeted PAD Genetic Conditions:

  • Parkinson’s Disease (PD)
  • Alzheimer’s Disease (AD)
  • Gaucher Disease
  • Segawa Syndrome
  • Nasu- Hakola DIsease
  • Gerstmann- Straussler Disease
  • Creutzfeldt- Jakob Disease
  • Alpers Syndrome
  • Cerebral Arteriopathy with Subcortical Infarcts and Leukoencephalopathy (CADASIL)
  • Amyotrophic Lateral Sclerosis (ALS)

Helix Lab Solutions offers comprehensive Parkinson’s-Alzheimer’s-Dementia (PAD) genetic testing to allow providers earlier intervention treatments. This genetic testing helps providers to form optimal individualized patient care plans at low costs to make the best clinical decisions for their patients.

Helix Lab Solutions offers PAD Genetic Testing because over 5.8 million people living in America suffer from Alzheimer's Dementia.

1 million (17%) are 65-74 years old.

2.7 million (47%) are 75-84 years old.

2.1 million (36%) are 85+ years old.

Helix Lab Solutions uses Next Generation Sequencing technology to examine 35 genes associated with an increased risk for developing neurodegenerative diseases. This is important because in the year 2020, there were close to 1 million Americans suffering from Parkinson’s Disease. And that number is only increasing.

Helix Lab Solutions paves the way for earlier intervention and treatment. Treatment for PAD includes: psychosocial treatment, research study enrollment, and support programs. This genetic testing is important because it also allows the patient to notify other at risk family members because they have a 50% chance of inheriting the same disease.